文献速递淋巴瘤造血干细胞移植与细胞治疗

维布妥昔单抗联合化疗治疗复发/难治性霍奇金淋巴瘤:倾向性评分匹配分析

Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.
PubMed 文献 · Blood Adv · 2024-01-01

该研究纳入10项临床试验的768例适合移植的复发/难治性经典型霍奇金淋巴瘤患者,其中386例接受含或不含化疗的维布妥昔单抗(BV队列),382例仅接受化疗(化疗队列),倾向性评分匹配后各240例。匹配队列间移植前完全代谢缓解率(P=.69)和无进展生存期(P=.14)无显著差异;但在复发患者中,BV队列3年无进展生存期显著优于化疗队列(80% vs 70%,P=.02),而原发难治患者中无差异(56% vs 62%,P=.67)。

要点

  • 匹配后BV队列与化疗队列移植前完全代谢缓解率无显著差异(P=.69)。
  • 复发患者中BV队列3年无进展生存期80% vs 化疗队列70%(P=.02)。
  • 原发难治患者中两组3年无进展生存期无差异(56% vs 62%,P=.67)。

核心结论

  • 含或不含挽救化疗的维布妥昔单抗似乎可改善复发患者的无进展生存期,但在原发难治性经典型霍奇金淋巴瘤患者中未见改善。

研究设计与样本

  • 该研究为倾向性评分匹配分析,纳入10项临床试验的个体患者数据,共768例适合移植的复发/难治性经典型霍奇金淋巴瘤患者;BV队列386例接受含或不含化疗的维布妥昔单抗,化疗队列382例仅接受化疗;倾向性评分匹配后各240例。

主要发现

  • 匹配队列间移植前完全代谢缓解率无显著差异(P=.69),无进展生存期无显著差异(P=.14)。
  • 复发患者中,BV队列3年无进展生存期显著优于化疗队列(80% vs 70%,P=.02)。
  • 原发难治患者中,BV队列与化疗队列3年无进展生存期无差异(56% vs 62%,P=.67)。
  • IV期患者在BV队列中3年无进展生存期显著更优(P=.015)。
  • BV单药后达到完全代谢缓解者与BV序贯化疗者的移植后无进展生存期相当(P=.24)。

临床怎么用

  • 作者认为,含或不含挽救化疗的维布妥昔单抗似乎可改善复发患者的无进展生存期,但在原发难治性经典型霍奇金淋巴瘤患者中未见改善。

局限性

  • 原文指出,BV队列3年总生存率较高可能归因于疾病进展后后续治疗中使用了其他新型疗法,因BV队列研究开展时间更近。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no head-to-head comparisons with standard salvage chemotherapy have been performed. This study presents a propensity score-matched analysis encompassing individual patient data from 10 clinical trials to evaluate the impact of BV in transplant-eligible patients with R/R cHL. We included 768 patients, of whom 386 were treated with BV with or without chemotherapy (BV cohort), whereas 382 received chemotherapy alone (chemotherapy cohort). Propensity score matching resulted in balanced cohorts of 240 patients each. No significant differences were observed in pre-ASCT complete metabolic response (CMR) rates (P = .69) or progression free survival (PFS; P = .14) between the BV and chemotherapy cohorts. However, in the BV vs chemotherapy cohort, patients with relapsed disease had a significantly better 3-year PFS of 80% vs 70%, respectively (P = .02), whereas there was no difference for patients with primary refractory disease (56% vs 62%, respectively; P = .67). Patients with stage IV disease achieved a significantly better 3-year PFS in the BV cohort (P = .015). Post-ASCT PFS was comparable for patients achieving a CMR after BV monotherapy and those receiving BV followed by sequential chemotherapy (P = .24). Although 3-year overall survival was higher in the BV cohort (92% vs 80%, respectively; P < .001), this is likely attributed to the use of other novel therapies in later lines for patients experiencing progression, given that studies in the BV cohort were conducted more recently. In conclusion, BV with or without salvage chemotherapy appears to enhance PFS in patients with relapsed disease but not in those with primary refractory cHL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Driessen J, de Wit F, Herrera AF, et al. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis. Blood Adv. 2024. PMID: 38502227. doi:10.1182/bloodadvances.2023012145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。